ARTICLE | Clinical News
VRI antagonist: Phase I started
August 11, 2008 7:00 AM UTC
Pfizer began a double-blind, placebo-controlled, single ascending-dose Phase I trial in healthy volunteers with an oral VR1 antagonist. Pfizer and Renovis Inc., which was recently acquired by Evotec...